[1] Go A S, Glenn M. Chronic kidney disease and the risk of death, cardiovascular events, and hospitalization [J]. N Engl J Med, 2004, 351(13): 1296-1305.
[2] Foley R N, Parfrey P S, Sarnak M J. Clinical epidemiology of cardiovascular disease in chronic renal disease [J]. Am J Kidney Dis, 2005, 101(3):112-119.
[3] Wanner C, Krane W, Mrz W, et al. Atrovastatin in patients with type 2 diabetes mellitus undergoing hemodialysis [J]. N Engl J Med, 2005, 353(2): 238-248.
[4] Evenepoel P, Meijers B, Viaene L, et al. Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism [J]. Clin J Am Soc Nephrol, 2010, 5(7): 1268-1276.
[5] Isakova T, Wahl P, Vargas G S, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease [J]. Kidney Int, 2011, 79(12): 1370-1378.
[6] Kendrick J, Cheung A K, Kaufman J S, et al. FGF-23 associates with death, cardiovascular events, and initiation of chronic chronic dialysis [J]. J Am Soc Nephrol, 2011, 22(10): 1913-1922.
[7] Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis [J]. J Bone Miner Res, 2004, 19: 429-435.
[[8]] Eswarakumar Y P, Lax I, Schlissinger J. Cellular signaling by fibroblast growth factor receptor [J]. Cytokine and Growth Factor Reviews, 2005, 16(2): 139-149.
[[9]] Yu X, Ibrahimi O A, Goetz R, et al. Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23 [J]. Endocrinology, 2005, 146(11): 4647-4656.
[10] Yamazaki M, Ozono K, Okada T, et al. Both FGF23 and extracellular phosphate active Raf/MEK/ERK pathway via FGF receptors in HEK293 cells [J]. Journal of Cellular Biochemistry, 2010, 111(5): 1210-1221.
[11] Nitta K, Nagano N, Tsuchiya K. Fibroblast growth factor23/Klotho axis in chronic kidney disease [J]. Nephron Clin Pract, 2014, 128(1): 1-10.
[12] Shimada T, Kakitani M, Yamaaki Y, et al. Targeted ablation of FGF23 demonstrates an essential physiological role of FGF-23 in phosphate and vitamin D metabolism [J]. Journal of Clinical Investigation, 2004, 113(4): 561-568.
[13] Takaiwa K, Nagano N, Nitta K. Klotho/FGF23 Axis in CKD [J]. Contrib Nephrol, 2015, 185: 56-65.
[14] Komaba H, Fukagawa M. FGF23-parathyroid interaction: implications in chronic kidney disease [J]. Kidney Int, 2010, 77(4): 292-298.
[15] Ben-Dov I Z, Galitzer H, Lavi-Moshayoff T, et al. The parathyroid is a target organ for FGF23 in rats [J]. Joural of Clinical Investigation, 2007, 117(12): 4003-4008.
[16] Isakova T, Xie H, Yang W, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease [J]. JAMA, 2011, 305 (23): 2432-2439.
[17] Hofman-Bang J, Martuseviciene G, Santini M A, et al. Increased parathyroid expression of Klotho in uremic rats [J]. Kidney Int, 2010, 78(11): 1119-1127.
[18] 白 冰, 王彩丽,吕 丽,等. 慢性肾脏病患者血管钙化与成纤维细胞生长因子23-Klotho轴的关系 [J]. 国际移植与血液净化杂志, 2017,15(2): 17-22.
[19] Quarles L D. Role of FGF23 in vitamin D and phosphate metabolism: Implications in chronic kidney disease [J]. Exp Cell Res, 2012, 318(9): 1040-1048.
[20] Tsuchiya K, Nagano N, Nitta K. Klotho/FGF23 Axis in CKD [J]. Contrib Nephrol, 2015, 185: 56-65.
[21] Hasegawa H, Nagano N, Urakawa, I, et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease [J]. Kidney Int, 2010, 78(10): 975-980.
[22] Shanahan C M, Crouthamel M H, Kapustin A, et al. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate [J]. Circulation Research, 2011, 109(6): 697-711.
[23] Adeney K L, Siscovick D S, Ix J H, et al. Association of serum phosphate with vascular and valvular calcification in moderate CKD [J]. Journal of the American Society of Nephrology, 2009, 20(1): 381-387.
[24] Li X, Yang H.-Y, Mckee CE, et al. Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification [J]. Circulation Research, 2009, 104(6):733-741.
[25] Speer M Y, Yang H Y, Brabb T, et al. Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries [J]. Circulation Research, 2009, 104(6): 733-741.
[26] Villa-Bellosta R, Bogaert Y E, Levi M, et al. Characterization of phosphate transport in rat vascular smooth muscle cells: implications for vascular calcification [J]. Arteriosclerosis Thrombosis and Vascular Biology, 2007, 27(5): 1030-1036.
[27] Isakova T, Wahl P, Vargas G S, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease [J]. Kidney Int, 2011, 79: 1370-1378.
[28] Lee X Y, Ng H Y, Chiu T T, et al. Association of bone-derived biomarkers with vascular calcification in chronic hemodialysis patients [J]. Clin Clim Acta, 2016, 452(15): 38-43.
[29] Zhang M, Yan J, Zhu M, et al. Fibroblast growth factor 23 predicts coronary calcification and poor prognosis in patients with chronic kidney disease stages 3-5D [J]. Ann Clin Lab Sci, 2015, 45:17-22.
[30] Raggi P, Bellasi A, Gamboa C, et al. All-cause mortality in hemodialysis patients with heart valve calcification [J]. Clin J Am Soc Nephrol, 2011, 6: 1991-1995.
[31] Silva A P, Gundlach K, Büchel J, et al. Low magnesium levels and FGF23 dysregulation predict mitral valve calcification as well as intima media thickness in predialysis diabetic patients [J]. Int J Endocrinol, 2015, 2015: Article ID: 308190.
[32] 王晓鸿, 吕宝军, 熊重祥, 等. 血液透析患者血浆FGF23水平与颈动脉粥样硬化关系的研究 [J]. 中国中西医结合肾病杂志,2011, 12(4): 321-323.
[33] Desjardins L, Liabeuf S, Renard C, et al. FGF23 is independently acciated with vascular calcification but not bone mineral density inpatients at various CKD stages [J]. Osteoporos Int, 2012, 23(7): 2017-2025.
[34] Sapir-Korren R, Livshits G. Bone mineralization in regulated by signaling cross talk between molecular factors of local and systemic origin: The role of fibroblast growth factor 23 [J]. Biofactors, 2014, 40(6): 555-568.
[35] Faul C, Anlaral A P, Oskouei B, et al. FGF23 induces left ventricular hypertrophy [J]. J Clin invest, 2011, 121(11):N4393-4408.
[36] Negri A L. Fibroblast growth factor 23:Associations with cardiovascular disease and mortality in chronic kidney disease [J]. Int Urol Nephrol, 2014, 46(1): 9-17.
[37] Di Marco G S, Renter S, Kentrup D, et al. Treatment of established left ventricular hypertrophy with fibroblast growth factor receptor blocked in an animal model of CKD [J]. Nephrol Dial Transplant, 2014, 29(1): 2028-2035.